A comparative study of renoprotective effect of tolvaptan as an alternative treatment for increasing loop diuretics in patients with chronic kidney disease complicated with chronic heart failure
Not Applicable
- Conditions
- chronic heart failure, chronic kidney disease
- Registration Number
- JPRN-UMIN000036119
- Lead Sponsor
- Kawashima hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who cannot intake fluids or feel thirst Patients with anuria or urinary excretion disorder Patients with hypernatremia Patients with serious hepatic disorder Patients under the pacing therapy Patients with percutaneous coronary intervention or open heart surgery within the past 3 months Patients with poorly controlled diabetes mellitus Patients who take SGLT-2 inhibitor Patients who are pregnant or possibly pregnant Patients without agreement on enrolment of this study Inappropriate patients judged by doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum creatinine level eGFR change from baseline Worsening renal function (WRF) from 1 days to 1 years later Days until the dialysis induction Dialysis induction rate
- Secondary Outcome Measures
Name Time Method urine volume, body weight, blood pressure, heart rate, plasma BNP, echocardiography (inferior vena cava diameters, ejection fraction), chest X ray (cardio-thoracic ratio, pulmonary congestion), urine osmolality, Fractional Excretion of Na (FENa), serum BUN, serum Na, serum K , New York heart association cardiac functional classification, cardiovascular event rate